BENTLEY'S EUROPEAN SUBSIDIARIES RECEIVE NEW MARKETING APPROVALS

Bentley Pharmaceuticals, Inc. (NYSE: BNT), a technology-based specialty pharmaceutical and drug delivery company with a growing branded and generic product line in Europe, today announced that Laboratorios Davur has acquired the rights to market 10mg, 20mg, 40mg and 80mg dosage levels of pravastatin in Spain. Additionally, two of its Spanish subsidiaries (Davur and Rimafar) have each received approvals to market 250mg, 500mg and 750mg branded and generic versions of ciprofloxacin in Spain.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20051020005124&newsLang=en)